Meningococcal Group B vaccine (Trumenba®)

Phase 3

Sanofi (SNY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Meningococcal Immunisation (Healthy Volunteers)

View Full Landscape

Drug Information

Target Indication

Meningococcal Immunisation (Healthy Volunteers)

Clinical Trial

NCT04084769

Last updated: 10/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/24/2017

Trumenba

Trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B. The use of this vaccine should be in accordance with official recommendations.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

zolpidem-MR (SL800750)Phase 3

Sleep Initiation and Maintenance Disorders

efanesoctocog alfa (BIVV001)Phase 3

Hemophilia A

DuvakitugPhase 3

Ulcerative Colitis

xaliproden (SR57746A)Phase 3

Alzheimer Disease

A/H1N1 pandemic influenza vaccine (non- adjuvanted)Phase 3

Influenza

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts